An Observational Retrospective Matched Cohort Study of Healthcare Resource Utilisation and Costs in UK Patients with Moderate to Severe Osteoarthritis Pain.
Analgesia
Arthroplasty
Chronic pain
England
Healthcare cost
Hospitalisation
Length of stay
Osteoarthritis
Primary health care
Regional health planning
Journal
Rheumatology and therapy
ISSN: 2198-6576
Titre abrégé: Rheumatol Ther
Pays: England
ID NLM: 101674543
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
23
11
2021
accepted:
08
02
2022
pubmed:
22
3
2022
medline:
22
3
2022
entrez:
21
3
2022
Statut:
ppublish
Résumé
Using data from patients residing in Salford, UK, we aimed to compare healthcare resource utilisation (HCRU) and direct healthcare costs between patients with moderate to severe (M-S) or severe osteoarthritis (OA) pain and those without OA. Patients with a M-S OA pain event within a period of chronic pain were indexed from the Salford Integrated Record (SIR) between 2010 and 2017. Patients with a severe pain event formed an OA subcohort. Patients in each OA pain cohort were independently matched to patients without OA, forming two control cohorts. HCRU, prescribed analgesic drugs, and total direct costs per UK standardised tariffs were calculated for the year post-index. Multivariable models were used to identify drivers of healthcare cost. The M-S OA pain and control cohorts each comprised 3123 patients; the severe OA pain and control cohorts each comprised 1922 patients. Patients in both OA pain cohorts had a significantly higher mean number of general practitioner encounters, inpatient, outpatient, and accident and emergency visits, and were prescribed a broader range of analgesic drugs in the year post-index than respective controls. Mean healthcare costs of all types were significantly higher in the M-S and severe OA pain cohorts vs controls (total: M-S £2519 vs £1379; severe £3389 vs £1397). Paracetamol (M-S: 40% of patients had at least one prescription; severe: 50%) and strong opioids (34% and 59%) were the analgesics most prescribed to patients with OA pain. In all cohorts, multivariable models showed that a higher age at index, the presence of gout, osteoporosis, type 2 diabetes, or coronary artery disease, significantly contributed towards higher healthcare costs. In the population of Salford, UK, patients with M-S OA pain had significantly higher annual HCRU and costs compared with matched controls without OA; generally, these were even higher in patients with severe OA pain.
Identifiants
pubmed: 35312946
doi: 10.1007/s40744-022-00431-2
pii: 10.1007/s40744-022-00431-2
pmc: PMC9127021
doi:
Types de publication
Journal Article
Langues
eng
Pagination
851-874Informations de copyright
© 2022. The Author(s).
Références
Osteoarthritis Cartilage. 2008 Feb;16(2):137-62
pubmed: 18279766
BMJ. 2018 Jan 2;360:j5554
pubmed: 29295813
Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):711-719
pubmed: 32772591
Rheumatology (Oxford). 2014 May;53(5):937-47
pubmed: 24489012
Br Med Bull. 2013;105:185-99
pubmed: 23337796
Adv Ther. 2020 Sep;37(9):3985-3999
pubmed: 32729010
Health Qual Life Outcomes. 2012 Mar 15;10:30
pubmed: 22420468
Lancet Public Health. 2020 Oct;5(10):e543-e550
pubmed: 32979305
Arthritis. 2012;2012:698709
pubmed: 23082249
BMC Fam Pract. 2015 Oct 14;16:163
pubmed: 26530162
Ther Clin Risk Manag. 2021 Apr 21;17:345-356
pubmed: 33911870
Lancet. 1999 Oct 9;354(9186):1248-52
pubmed: 10520633
J Pain Res. 2020 Dec 23;13:3415-3425
pubmed: 33380823
BMC Musculoskelet Disord. 2021 Mar 31;22(1):317
pubmed: 33789636
Rheumatol Ther. 2021 Mar;8(1):303-326
pubmed: 33411324
Pain. 2022 Jan 1;163(1):75-82
pubmed: 34924552
BMC Musculoskelet Disord. 2021 Jan 7;22(1):40
pubmed: 33413273
BMJ Open. 2018 Jan 27;8(1):e019146
pubmed: 29374669
Ther Adv Musculoskelet Dis. 2020 Sep 17;12:1759720X20942000
pubmed: 32994809
Osteoarthritis Cartilage. 2013 Sep;21(9):1145-53
pubmed: 23973124
Arthritis Res Ther. 2010;12(4):R162
pubmed: 20738855
Osteoarthritis Cartilage. 2014 Mar;22(3):363-88
pubmed: 24462672
BMJ Open. 2016 Jun 20;6(6):e010364
pubmed: 27324708
Drug Saf. 2015 Jul;38(7):671-82
pubmed: 26100143
J Manag Care Spec Pharm. 2019 Sep;25(9):957-965
pubmed: 31456495
Clin Exp Rheumatol. 2021 Jul-Aug;39(4):819-828
pubmed: 32896256
J Med Econ. 2019 Nov;22(11):1192-1201
pubmed: 31433685
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
Rheumatology (Oxford). 2017 Nov 1;56(11):1902-1917
pubmed: 28977564
Lancet. 2018 Nov 3;392(10158):1647-1661
pubmed: 30497795
Arthritis Res Ther. 2013;15(5):R106
pubmed: 24008023
Ann Rheum Dis. 2003 Dec;62(12):1145-55
pubmed: 14644851
Postgrad Med. 2021 Jan;133(1):10-19
pubmed: 33131380
BMC Med Inform Decis Mak. 2015 Feb 07;15:8
pubmed: 25880660